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Abstract
There are several different types of drug delivery 
interfaces available on the market. Using the right inter-
face for aerosol drug delivery to children is essential for 
effective inhalation therapy. However, clinicians usually 
focus on selecting the right drug-device combination 
and often overlook the importance of interface selection 
that lead to suboptimal drug delivery and therapeutic 
response in neonates and pediatrics. Therefore, it 
is necessary to critically assess each interface and 
understand its advantage and disadvantages in aerosol 
drug delivery to this patient population. The purpose 
of this paper is to provide a critical assessment of drug 
delivery interfaces used for the treatment of children 
with pulmonary diseases by emphasizing advantages 
and problems associated with their use during inhalation 
therapy. 
Key words: Aerosols; Inhalation therapy; Children; 
Masks; Mouthpiece; High flow nasal cannula; Blow-by; 
Hood; Spacer/valved holding chamber
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Core tip: Many interfaces exist for aerosol drug delivery 
to spontaneously breathing children and inhalation 
therapy with different interfaces has become an impor-
tant topic of interest among clinicians. However, clini-
cians usually focus on selecting the right drug-device 
combination and often overlook the importance of 
interface selection that lead to suboptimal drug delivery 
and therapeutic response in neonates and pediatrics. 
This paper provides a critical assessment of drug 
delivery interfaces used for the treatment of children 
with pulmonary diseases by emphasizing advantages 
and problems associated with their use during inhalation 
therapy.
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INTRODUCTION
There are several different types of drug delivery 
interfaces available on the market. Using the right 
interface for aerosol drug delivery to children is essential 
for effective inhalation therapy. However, clinicians 
usually focused on selecting the right drug-device 
combination and often overlooked the importance 
of interface selection that lead to suboptimal drug 
delivery and therapeutic response in neonates and 
pediatrics[1-6]. Therefore, it is necessary to critically 
assess each interface and understand its advantage 
and disadvantages in aerosol drug delivery to neonates 
and pediatrics. The purpose of this paper is to provide a 
critical assessment of drug delivery interfaces used for 
the treatment of children with pulmonary diseases by 
emphasizing advantages and problems associated with 
their use during inhalation therapy. 
BLOW-BY
Blow-by is a technique that is used with a jet nebulizer 
placed within a distance from the child and directs 
aerosol plume towards the patient’s face. Historically, 
aerosolized medications were delivered to neonates 
and pediatrics using blow-by because it was considered 
to be an effective technique especially for crying, 
fussing and uncooperative children. Also, many parents 
preferred to use blow-by, a mask-free aerosol delivery 
technique, to avoid struggling with their children during 
inhalation therapy. 
However, there are several disadvantages of this 
technique. For instance, it cannot be used with pres-
surized metered-dose inhalers (pMDIs) with valved 
holding chambers (VHCs) and breath-actuated nebuli-
zers due to poor mask seal that will inhibit valve 
opening[7]. Also, blow-by cannot be used with mesh 
nebulizers due to lack of supplemental gas flow[7]. 
Previous research reported that blow-by is not efficient 
in aerosol drug delivery to children because it results 
in 50%-85% lower dose than the facemask[8-11]. 
Therefore, using blow-by for aerosol therapy is not 
recommended[7,11-13].
Problems associated with blow-by highlight not 
only the importance of interface selection in inhalation 
therapy, but also finding a better alternative for deli-
vering aerosolized medications to neonates and 
pediatrics. Mouthpiece, facemask, nasal mask, pasifier 
mask, hood, high flow nasal cannula and VHCs may be 
viable choices of interface in children and the following 
sections will describe each interface more in detail.
MOUTHPIECE
Previous in vitro studies showed that aerosol delivery 
via a mouthpiece may provide twice as much drug 
compared with a facemask and is the most effective inter-
face in spontaneously breathing older pediatrics[14,15]. 
Since children less than 3 years of age cannot keep the 
mouthpiece in their mouth with an adequate seal during 
inhalation therapy, the mouthpiece is not the right 
interface for them[16-19]. Therefore, when a mouthpiece 
cannot be used by a child, choosing another interface 
such as facemask, high flow nasal cannula or hood 
is important to improve the efficiency and efficacy of 
aerosol drug delivery to neonates and pediatrics. 
FACEMASK
Facemasks are commonly used for aerosol drug delivery 
to children until they develop sufficient understanding 
to inhale through the mouthpiece during inhalation 
therapy. In children who cannot use a mouthpiece until 
3 years of age, clinicians should consider using a well-
fitting facemask. Therefore, it is essential to select 
a lightweight and flexible facemask with anatomic 
contours and small dead space in order to increase 
tolerability of facemask by children during inhalation 
therapy[20,21]. Using smaller masks with less dead space 
in neonates will lead to a greater inhaled dose especially 
with use of aerosol devices such as mesh nebulizers 
or pMDIs that do not add gas to the system during 
treatment.
Facemasks designs can be divided into two cate-
gories: (1) front-loaded facemasks and (2) bottom-
loaded facemasks. Front-loaded facemasks have 
small entrainment ports on the side of the mask and 
direct aerosol toward the oronasal area of the patient 
as opposed to bottom-loaded masks that direct 
aerosol toward the upper part of the mask. Previous 
research reported that aerosol deposition with the 
front-loaded facemask (Bubbles Fish II Mask, PARI, 
Midlothian, Virginia) was greater than bottom-loaded 
facemask[8,22-24]. They also have lower deposition in the 
eye and face compared with bottom-loaded facemask 
designs[22,23,25].
When a facemask is used for aerosol drug delivery 
to neonates or pediatrics, clinicians should have a good 
face-mask seal to maximize the efficiency of treatment 
and prevent the drug from getting to the eyes and the 
face of children. However, keeping a good face-mask 
seal during inhalation therapy is frequently associated 
with crying and rejection of the facemask. Previous 
research showed that aerosol drug delivery to children 
will decrease significantly without an optimum face-mask 
seal because of leaks, crying or children intolerance of 
the facemask[2-4,22,25-29]. Janssens et al[30] suggested that 
administration of inhaled medications while children are 
asleep may be a viable option for inhalation therapy 
because children have more regular breathing patterns 
during sleep that may lead to greater lung deposition 
and better patient outcomes. However, Esposito-
Festen et al[31] reported that 69% of the young children 
woke up and 75% of them distressed during inhalation 
therapy with the pMDI and VHC combination.
In the past, clinicians believed that crying improves 
aerosol drug delivery to children because of the large 
breath at the end of the cry. However, crying results in a 
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very long exhalation followed by fast and short inhalation 
that leads to deposition of aerosolized medications in 
the upper respiratory track than in the lower respiratory 
therapy track. Also, it is difficult to have a good seal with 
the facemask when a baby cries. Using a facemask with 
the pMDI - VHC, Tal et al[32] found that lung deposition 
of babies crying was 0.35% as opposed to 2% when 
they have quite breating. Similarly, Murakami et al[33] 
showed that aerosol deposition in a crying infant using 
a facemask with a nebulizer was negligible and Iles 
et al[34] reported a 4-fold decrease in lung deposition 
when infants were crying. According to the findings 
of the study conducted by Wildhaber et al[35] the 
gastrointestinal deposition in crying children was 50% 
higher than their non-crying peers. 
PACIFIER MASK
As a new and innovative development of chidren-
oriented drug delivery interface, the pacifier mask 
(Soother Mask, InspiRx, Somerset, New Jersey) was 
designed to achieve therapeutic lung deposition in 
children by eliminating their discomfort, fear and cry 
with the conventional facemask and keeping them calm 
through a pacifier. It includes the infant’s own pacifier 
that is attached to the anterior wall of the mask (Figure 
1). The infant keeps the Soother mask sealed to his face 
by sucking the pacifier during treatment while nasally 
inhaling aerosolized medications generated by pMDIs/
VHCs or nebulizers during inhalation therapy[36,37]. Amirav 
et al[38] compared the Soother mask with a conventional 
bottom-loaded face mask on bronchodilator delivery in 
12 infants less than 1 year of age. Using scintigraphic 
measurements of aerosol deposition in infants, they 
reported that lung deposition with the Soother Mask 
was similar to that with the conventional face mask 
without a pacifier[38]. Since sucking calms children, the 
Shooter Mask can be used for prolonged periods of time 
without rejection by infants and improves compliance to 
aerosol treatments in infants[18,36-38]. 
HIGH FLOW NASAL CANNULA
Infants and young children are nose breathers. 
Since previous research showed that nasal delivery 
of aerosolized medications to the lungs of infants 
and pediatrics is superior or more effective than oral 
delivery[39,40], aerosol delivery through high flow nasal 
cannula (HFNC) has become a popular procedure in 
the treatment of children with pulmonary diseases. 
Several in vitro studies evaluated aerosol drug delivery 
through HFNC in infants and pediatrics[41-44]. Using 
dose quantification with the laser diffraction technique, 
Bhashyam et al[43] determined the efficiency of inhalation 
therapy through adult and pediatric HFNC with a mesh 
nebulizer placed downstream of a heated humidifier. 
They reported that aerosolized medications could be 
efficiently delivered to pediatrics through HFNC. Ari 
et al[44] compared aerosol drug delivery with helium-
oxygen mixture (heliox) and oxygen at 3 L/min and 6 
L/min, using a pediatric HFNC with a mesh nebulizer 
placed on the inspiratory inlet of a heated humidification 
system. They reported that bronchodilator delivery 
with heliox at 3 L/min was similar to that with oxygen 
whereas heliox delivered 2 fold greater aerosol than 
oxygen at 6 L/min. Sunbul et al[42] evaluated bron-
chodilator delivery using HFNC, bubble continuous 
positive airway pressure (CPAP) and sigh intermittent 
mandatory ventilation (SiPAP) with a mesh nebulizer 
placed proximal to the patient interface and prior to 
the humidifier. Using spontaneously breathing lung 
model attached to a low-birth-weight anatomic nasal 
airway cast, they showed that aerosol delivery with 
SiPAP was lower than HFNC and the Bubble CPAP. 
Aerosol deposition through HFNC was less than 2% 
but higher than drug delivery with the Bubble CPAP. 
Also, nebulizer placement at the humidifier resulted in 
greater aerosol deposition in HFNC, SiPAP and Bubble 
CPAP[42]. According to Perry et al[41] HFNC should not be 
used for bronchodilator delivery to children because the 
amount of aerosol deposition obtained with different 
cannula sizes of flows used with HFNC was lower than 
the amount needed for a clinical response. Also, skin 
irritation and condensate accumulating in the cannula 
are potential issues with HFNC. Therefore, clinical 
studies evaluating the safety and efficacy of aerosol 
drug delivery with HFNC are warranted.
NASAL MASK
Nasal masks were developed in recent years to improve 
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Figure 1  Soother mask (Reproduced with permission from the 
InspiRx, Somerset, New Jersey).
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  Interface Description Advantages Disadvantages Suggestions for the best practice
  �low-by A technique that directs aerosol 
plume towards the patient’s face 
by placing a jet nebulizer within a 
distance from the child that ranges 
from 1 to 30 cm
Easy to use
Comfortable and easy to 
tolerate by the patient
A mask-free aerosol deli�ery 
technique 
Used with fussing, crying and 
uncooperati�e children
Inefficient aerosol drug delivery to 
children
Drug deli�ery with blow-by is 
50%-85% less than the facemask
Cannot be used with pMDIs, 
breath- actuated nebulizers and 
mesh nebulizers
Inhalation therapy with blow-
by is not efficient; therefore, it 
should not be used for aerosol 
drug deli�ery to neonates and 
pediatrics
  Mouthpiece A cylindrical tube that extends 
between the lips so that aerosol can 
pass through the oropharynx to reach 
lower respiratory tract
Efficient inhalation therapy in 
children
Aerosol drug deli�ery with a 
mouthpiece is two-fold more 
than that with a face mask
Children less than 3 yr of age 
cannot use a mouthpiece
An adequate consistent seal is 
needed during inhalation therapy
The mouthpiece should not be 
used for children who are less 
than 3 yr old
When using a mouthpiece child 
should be encouraged to keep it 
in their mouth during therapy
If a child cannot keep the 
mouthpiece in his mouth with 
an adequate seal during aerosol 
drug deli�ery, another interface 
should be used for inhalation 
therapy
  Facemask An interface that co�ers the nose and 
mouth. It is kept in place through an 
elastic band that extends beyond the 
back of the head or neck
Can be used in children all 
years of age
Can be used with nebulizers 
and pMDIs to deli�er 
aerosolized medications to 
neonates and pediatrics
A good facemask seal is needed for 
optimum aerosol drug deli�ery
Is frequently associated with 
crying, intolerance and rejection of 
the mask
Crying and leaks between face 
and mask decrease aerosol drug 
deli�ery to children
Select a lightweight and flexible 
facemask with anatomic 
contours to increase tolerability 
of face mask by children during 
therapy
Choose a facemask with small 
dead space and ha�e a good 
face-mask seal to increase 
delivery efficiency of inhalation 
therapy
Use another interface if the 
patient starts to fuss, and cry 
during aerosol drug deli�ery 
with a facemask
  Pacifier mask A face mask with the attachment of 
the infant’s own pacifier
A new and inno�ati�e 
facemask design that 
eliminates fear, discomfort 
and cry with the standard 
facemask
A children-oriented drug 
deli�ery interface designed 
to achie�e therapeutic lung 
deposition in children
Impro�es compliance to 
inhalation therapy in infants
May be a good option for 
children who fuss, cry and does 
not tolerate other interfaces used 
for aerosol drug deli�ery in 
neonates and pediatrics
  Nasal mask An interface that co�ers the nose 
to allow aerosol to pass through 
the nasopharynx to reach the lower 
respiratory tract
Easy to use
�etter tolerance than the 
facemask
Aerosol deli�ery with the nasal 
mask is less than that with the 
standard facemask
  High flow 
  nasal 
  cannula
A tubing with two small prongs that 
are inserted into the nares to allow 
aerosol pass through the nasopharynx 
and reach the lower respiratory tract
Efficient delivery of 
aerosolized medications to 
neonates and pediatrics
Children may tolerate HFNC 
better than the facemask
More information about the 
safety and efficacy of aerosol drug 
deli�ery though HFNC is needed
Cannot be used with pMDIs
When using mesh nebulizers 
for aerosol drug deli�ery to 
neonates and pediatrics, place 
the nebulizer prior to the heated 
humidifier
  Hood An enclosure that co�ers the head 
and neck of a neonate or small 
children to deli�er aerosol to the 
lungs while isolating it from ambient 
air
A good option for aerosol 
deli�ery to children who 
cannot use a mouthpiece and 
tolerate the facemask
Likelihood of agitating infants 
and making them cry is low
Aerosol deli�ery with the 
hood is the same as the 
facemask
Parents prefer the hood o�er 
the mask
User may need additional training 
and practice to pro�ide proper 
inhalation therapy with the hood
More time and parts may be 
needed for the set-up
Use the hood for aerosol drug 
deli�ery to children who cannot 
use a mouthpiece and tolerate 
the facemask
Put the infant in the face-side 
position when using the hood 
for inhalation therapy because it 
has less facial-ocular deposition 
than face-up position
Table 1  Descriptions, advantages and disadvantages of each interface used for aerosol drug delivery to spontaneously breathing 
neonates and pediatrics
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aerosol drug delivery to neonates and pediatrics. The 
nasal mask is a special type of mask that is placed over 
the nasal airway during inhalation therapy. A recent in 
vitro study showed that aerosol delivery with the nasal 
mask was less than that with the facemask in simulated 
spontaneously breathing infants and young children 
using a jet nebulizer[24]. 
HOOD
Hood is a good option for aerosol drug delivery to 
children who cannot use a mouthpiece and tolerate the 
facemask[18,45-48]. Since there is no attachment to the 
patient’s face, the likelihood of agitating infants and 
making them cry with the use of hood for inhalation 
therapy may be less than facemasks. Aerosol drug 
delivery via hood is easy to operate and often provided 
when infants are asleep. Amirav et al[49] showed that 
bronchodilator delivery with the hood and facemask 
was similar (2.6% and 2.4%, respectively) in 14 
wheezing children. Kugelman et al[47] reported that both 
treatment time and discomfort were lower in infants 
using the hood. In another study, Amirav et al[48] found 
that respiratory scores of infants with bronchiolitis 
received aerosol therapy with the hood and facemask 
were similar, but parents preferred the hood over the 
masks[48]. It is also important to ensure the optimal 
position of the child within the hood. Kim et al[50] found 
similar lung deposition in face-up and face down posi-
tions during hood nebulization; however, the face-side 
position has less facial-ocular deposition than face-up 
position. 
VALVED-HOLDING CHAMBERS
VHCs are commonly used with pMDIs in order to decrea-
se oropharyngeal deposition and minimize hand-breath 
coordination in children[12,51]. According to previous 
research, spacers and VHCs should be washed with 
detergent and air-dry to eliminate static charge and 
improve aerosol delivery to infants and pediatrics[52-55]. 
Thus, deposition of drug particles on the inner surface 
of the spacer or VHC will be eliminated. Another alter-
native would be to use anti-static spacers/VHCs during 
inhalation therapy in children[56]. 
Also, infants and toddlers may not empty aerosolized 
medication from a large volume spacer of 200-700 mL. 
Therefore, it is important to use small volume spacers 
or VHCs so that the concentration of aerosol in the VHC 
is kept higher and children can inhale all the medication 
in less time with fewer breaths. Parents need to be 
educated to actuate one dose at a time into VHC instead 
of multiple doses and let their children inhale from VHC 
right after the pMDI has been actuated[12,57]. 
EDUCATING PARENTS ABOUT 
INTERFACES USED IN INHALATION 
THERAPY
Typically, inhaled medications are prescribed without 
demonstrating parents how inhalation therapy should be 
undertaken with each device and interface. Therefore, 
parents don’t know how to use each interface and how 
to solve problems that may arise during aerosol drug 
delivery to children. For instance, when their baby 
fights with the facemask, some parents may decide 
to use blow-by without knowing that it will reduce 
the efficiency of therapy and others force the baby to 
accept the facemask by holding it tightly on the baby’
s face and believing that crying improves aerosol drug 
delivery to their children. As a result, parents report 
poor response to inhalation therapy to their physicians 
who usually decide to increase the dose or change the 
inhaled agent as they assume parents’ technique in 
aerosol drug delivery is adequate[18]. Therefore, parental 
awareness and training on proper technique with each 
interface during inhalation therapy is essential. Table 1 
includes descriptions, advantages and disadvantages 
of each interface used for aerosol drug delivery to 
spontaneously breathing neonates and pediatrics. 
After careful instructions on how to use and handle an 
aerosol device, clinicians should reinforce instructions on 
a regular basis and the choice of drug delivery interface 
should be re-assessed[58].
In conclusion, delivering aerosolized drugs through 
different interfaces to children poses a number of 
challenges. Clearly, there is a need to develop more acce-
ptable and child-friendly interfaces in order to improve 
aerosol drug delivery to this patient population. New 
interfaces should take into account the special needs 
and respiratory characteristics of children. Meanwhile, 
educating parents and healthcare professionals about 
drug delivery interfaces used in inhalation therapy is 
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  Val�ed 
  holding 
  chamber
A chamber shaped interface with a 
one-way �al�e that allows aerosols to 







Improves efficiency of aerosol 
therapy
Electrostatic charge and large 
�olume VHCs result in a decrease 
in aerosol drug deli�ery to children
Wash the VHC with detergent 
and air dry before inhalation 
therapy in order to eliminate 
static charge and impro�e 
aerosol deli�ery to neonates and 
pediatrics
Choose small �olume VHCs for 
aerosol therapy
Actuate one-dose at a time into 
VHC instead of multiple doses
VHC: Val�ed holding chambers; pMDIs: Pressurized metered-dose inhalers.
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essential for the well-being of neonates and pediatrics.
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